欢迎来到天天文库
浏览记录
ID:53726550
大小:236.32 KB
页数:3页
时间:2020-04-20
《洛铂联合香菇多糖治疗恶性胸腔积液临床观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、I临扇研究Linchuangyanjiu《中国医学创新》第11卷第22期(总第3o4期)2014年8月洛铂联合香菇多糖治疗恶性胸腔积液临床观察贺敏①何兴鸿①【摘要】目的:观察胸腔内置管注入洛铂和香菇多糖治疗恶性胸腔积液的疗效。方法:收治恶性胸腔积液6O例,随机数字表法分为两组,经皮胸腔内置管引流尽胸液后,治疗组30例予胸腔内注入洛铂50mg+香菇多糖4mg,对照组3O例予顺铂4Omg/m注入胸腔。结果:治疗组总有效率和生活质量改善率均优于对照组(P2、性胸腔积液ClinicalObservationofMalignantPleuralEfusionofLobaplatinCombinedTreatmentofLentinan/HEMin,HEXing-hongJ/MedicalInnovationofChina。2014,11(22):080-082.【Abstract】Objective:Toobservelobaplatintheefectivenessandadversereactioninthetreatmentofmalignantpleuraleffusionbyinjectiontothoracicc3、avitywithlentinancombinedwithlobaplatinorcisplatinalone.Method:60patientswithmalignantpleuraleffusionweredividedintotwogroups,percutaneousintrathoracicdrainagetopleuraleffusion,30casesinthetreatmentgroupweretreatedwithintrapleuralinjectionoflobaplatin50mg+lentinan4mg,30casesinthecontrol4、grouptreatedwithcisplatin40mg/mwasinjectedintothepleuralcavity.Result:Thetotaleffectiverateandtheimprovementrateoflifequalitywasbetterthanthatofthecontrolgroup,withsignificantdiferences(P<0.05).Thetwogroupshadsimilarsideeffects.Conclusion:Chesttuberowsoflobaplatincombinedwithmushroomspo5、lysaccharideperfusionissafeandefectiveinthetreatmentofmalignantpleuraleffusion,operationisconvenient,effective,lessadversereactions,especiallysuitableforpatientswithadvancedcancerthroughmultipleplatinumchemotherapywithpleuralefusion.【Keywords】Lobaplatin;Cisplatin;Lentinan;Malignantpleur6、alefusionFirst-author’Saddress:JingmenHospitalofTraditionalChineseMedicineofHubeiProvinceOncology.Jingmen448000,Chinadoi:10.3969/j.issn.1674—4985.2014.22.027恶性胸腔积液由恶性肿瘤侵犯胸膜引起,多为晚本院肿瘤科住院治疗的晚期肿瘤合并胸腔积液患者60期肿瘤患者,该类患者胸腔积液生长迅速,常出现胸例,其中女19例,男4l例;年龄21~74岁,中位年闷、胸痛、呼吸困难等症状,严重影响患者的生活质量,龄52岁。KPS评分≥7、60分,KPS评分>60分,均无若不予治疗,生存期短】。目前常用的治疗方法为胸化疗禁忌证,经B超测定胸腔积液达到中等至大量,腔内注入顺铂等抗肿瘤药物,顺铂为近年来最常用的所有病例均为经病理学或细胞学检查确诊的晚期恶性胸腔内灌注化疗药物之一,其主要作用机制为影响肿肿瘤合并胸腔积液患者,且均有多次放化疗药物治疗瘤细胞DNA的合成及复制,能有效抑制或杀灭肿瘤细史,预计生存期≥1个月,其中肺癌18例,大肠癌3胞,刺激胸膜细胞增殖和纤维化,促进胸腔积液吸收,例,乳腺癌9例,卵巢癌11例,胃癌9例,宫颈癌5例,阻止胸腔积液渗出I2】。本院2009年11月一201
2、性胸腔积液ClinicalObservationofMalignantPleuralEfusionofLobaplatinCombinedTreatmentofLentinan/HEMin,HEXing-hongJ/MedicalInnovationofChina。2014,11(22):080-082.【Abstract】Objective:Toobservelobaplatintheefectivenessandadversereactioninthetreatmentofmalignantpleuraleffusionbyinjectiontothoracicc
3、avitywithlentinancombinedwithlobaplatinorcisplatinalone.Method:60patientswithmalignantpleuraleffusionweredividedintotwogroups,percutaneousintrathoracicdrainagetopleuraleffusion,30casesinthetreatmentgroupweretreatedwithintrapleuralinjectionoflobaplatin50mg+lentinan4mg,30casesinthecontrol
4、grouptreatedwithcisplatin40mg/mwasinjectedintothepleuralcavity.Result:Thetotaleffectiverateandtheimprovementrateoflifequalitywasbetterthanthatofthecontrolgroup,withsignificantdiferences(P<0.05).Thetwogroupshadsimilarsideeffects.Conclusion:Chesttuberowsoflobaplatincombinedwithmushroomspo
5、lysaccharideperfusionissafeandefectiveinthetreatmentofmalignantpleuraleffusion,operationisconvenient,effective,lessadversereactions,especiallysuitableforpatientswithadvancedcancerthroughmultipleplatinumchemotherapywithpleuralefusion.【Keywords】Lobaplatin;Cisplatin;Lentinan;Malignantpleur
6、alefusionFirst-author’Saddress:JingmenHospitalofTraditionalChineseMedicineofHubeiProvinceOncology.Jingmen448000,Chinadoi:10.3969/j.issn.1674—4985.2014.22.027恶性胸腔积液由恶性肿瘤侵犯胸膜引起,多为晚本院肿瘤科住院治疗的晚期肿瘤合并胸腔积液患者60期肿瘤患者,该类患者胸腔积液生长迅速,常出现胸例,其中女19例,男4l例;年龄21~74岁,中位年闷、胸痛、呼吸困难等症状,严重影响患者的生活质量,龄52岁。KPS评分≥
7、60分,KPS评分>60分,均无若不予治疗,生存期短】。目前常用的治疗方法为胸化疗禁忌证,经B超测定胸腔积液达到中等至大量,腔内注入顺铂等抗肿瘤药物,顺铂为近年来最常用的所有病例均为经病理学或细胞学检查确诊的晚期恶性胸腔内灌注化疗药物之一,其主要作用机制为影响肿肿瘤合并胸腔积液患者,且均有多次放化疗药物治疗瘤细胞DNA的合成及复制,能有效抑制或杀灭肿瘤细史,预计生存期≥1个月,其中肺癌18例,大肠癌3胞,刺激胸膜细胞增殖和纤维化,促进胸腔积液吸收,例,乳腺癌9例,卵巢癌11例,胃癌9例,宫颈癌5例,阻止胸腔积液渗出I2】。本院2009年11月一201
此文档下载收益归作者所有